Overview Dividends

(GKOS) Glaukos - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US3773221029

Stents, Implants, Pharmaceuticals, Devices, Therapeutics

GKOS EPS (Earnings per Share)

EPS Growth (3Y CAGR): 43.00%
EPS Trend (3Y Correlation): 80.3%

GKOS Revenue

Revenue Growth (3Y CAGR): 25.68%
Revenue Trend (3Y Correlation): 97.8%

Description: GKOS Glaukos November 06, 2025

Glaukos Corp (NYSE:GKOS) is an ophthalmic-focused pharma-tech firm that markets micro-invasive glaucoma surgery (MIGS) devices-including the iStent family, iStent infinite, iDose TR, iAccess blade, and iPRIME viscoelastic system-as well as pipeline platforms for keratoconus (iLink), drop-free drug delivery (ILution), and posterior-segment diseases (retinal XR). Its products are sold to ambulatory surgery centers, hospitals, and private practices via a mix of direct sales teams, subsidiaries, and distributors. The company, originally incorporated as Transdx in 1998, is headquartered in Aliso Viejo, California.

Key metrics (FY 2023): revenue of $374 million, representing a 12 % YoY increase driven primarily by a 28 % rise in iStent infinite sales; operating margin of 14 %; and a cash position of $210 million, giving a runway of roughly 18 months at current burn. The MIGS market is expanding at an estimated CAGR of 9 % through 2028, propelled by an aging U.S. population (≈ 12 % of adults ≥ 65 y) and growing physician adoption of minimally invasive procedures to meet Medicare Part B reimbursement incentives. A potential headwind is the tightening of reimbursement rates for device-based therapies, which could compress margins if adoption slows.

For a deeper quantitative assessment, you may find ValueRay’s analyst toolkit useful for modeling GKOS’s cash flow under different adoption scenarios.

GKOS Stock Overview

Market Cap in USD	5,038m
Sub-Industry	Health Care Equipment
IPO / Inception	2015-06-25

GKOS Stock Ratings

Growth Rating	3.98%
Fundamental	40.5%
Dividend Rating	-
Return 12m vs S&P 500	-47.2%
Analyst Rating	4.27 of 5

GKOS Dividends

Currently no dividends paid

GKOS Growth Ratios

Growth Correlation 3m	-66.1%
Growth Correlation 12m	-84%
Growth Correlation 5y	59.9%
CAGR 5y	17.46%
CAGR/Max DD 3y (Calmar Ratio)	0.33
CAGR/Mean DD 3y (Pain Ratio)	1.21
Sharpe Ratio 12m	-0.49
Alpha	-48.89
Beta	0.758
Volatility	48.04%
Current Volume	843.5k
Average Volume 20d	1121k
Stop Loss	78.2 (-6.7%)
Signal	-0.01

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-87.6m TTM) > 0 and > 6% of Revenue (6% = 28.2m TTM)

FCFTA -0.03 (>2.0%) and ΔFCFTA 6.13pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 78.17% (prev 90.36%; Δ -12.19pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.02 (>3.0%) and CFO -20.6m > Net Income -87.6m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 5.20 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (57.1m) change vs 12m ago 3.72% (target <= -2.0% for YES)

Gross Margin 76.87% (prev 76.61%; Δ 0.26pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 48.79% (prev 38.89%; Δ 9.90pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -9.74 (EBITDA TTM -81.3m / Interest Expense TTM 9.69m) >= 6 (WARN >= 3)

Altman Z'' -4.49

(A) 0.37 = (Total Current Assets 454.8m - Total Current Liabilities 87.5m) / Total Assets 999.4m

(B) -0.80 = Retained Earnings (Balance) -799.5m / Total Assets 999.4m

(D) -3.46 = Book Value of Equity -796.4m / Total Liabilities 229.8m

Total Rating: -4.49 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 40.51

1. Piotroski 1.0pt = -4.0

2. FCF Yield -0.55% = -0.28

3. FCF Margin -5.73% = -2.15

4. Debt/Equity 0.14 = 2.49

5. Debt/Ebitda -0.07 = -2.50

6. ROIC - WACC (= -21.25)% = -12.50

7. RoE -11.43% = -1.91

8. Rev. Trend 97.75% = 7.33

9. EPS Trend 80.30% = 4.02

What is the price of GKOS shares?

As of November 08, 2025, the stock is trading at USD 83.86 with a total of 843,454 shares traded.
Over the past week, the price has changed by -4.78%, over one month by -0.27%, over three months by -4.70% and over the past year by -39.81%.

Is Glaukos a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Glaukos (NYSE:GKOS) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 40.51 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GKOS is around 72.93 USD . This means that GKOS is currently overvalued and has a potential downside of -13.03%.

Is GKOS a buy, sell or hold?

Glaukos has received a consensus analysts rating of 4.27. Therefore, it is recommended to buy GKOS.

Strong Buy: 9
Buy: 3
Hold: 2
Sell: 0
Strong Sell: 1

What are the forecasts/targets for the GKOS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	119.2	42.2%
Analysts Target Price	119.2	42.2%
ValueRay Target Price	81.5	-2.8%

GKOS Fundamental Data Overview November 01, 2025

Market Cap USD = 5.04b (5.04b USD * 1.0 USD.USD)
P/E Forward = 1666.6667
P/S = 11.6375
P/B = 6.3331
P/EG = 1.64
Beta = 0.758
Revenue TTM = 469.8m USD
EBIT TTM = -94.4m USD
EBITDA TTM = -81.3m USD
Long Term Debt = 103.4m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 2.47m USD (from shortTermDebt, last fiscal year)
Debt = 104.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.07m USD (from netDebt column, last quarter)
Enterprise Value = 4.87b USD (5.04b + Debt 104.3m - CCE 273.7m)
Interest Coverage Ratio = -9.74 (Ebit TTM -94.4m / Interest Expense TTM 9.69m)
FCF Yield = -0.55% (FCF TTM -26.9m / Enterprise Value 4.87b)
FCF Margin = -5.73% (FCF TTM -26.9m / Revenue TTM 469.8m)
Net Margin = -18.65% (Net Income TTM -87.6m / Revenue TTM 469.8m)
Gross Margin = 76.87% ((Revenue TTM 469.8m - Cost of Revenue TTM 108.7m) / Revenue TTM)
Gross Margin QoQ = 78.41% (prev 78.33%)
Tobins Q-Ratio = 4.87 (Enterprise Value 4.87b / Total Assets 999.4m)
Interest Expense / Debt = 5.56% (Interest Expense 5.80m / Debt 104.3m)
Taxrate = -1.46% (negative due to tax credits) (234.0k / -16.0m)
NOPAT = -95.7m (EBIT -94.4m * (1 - -1.46%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 5.20 (Total Current Assets 454.8m / Total Current Liabilities 87.5m)
Debt / Equity = 0.14 (Debt 104.3m / totalStockholderEquity, last quarter 769.5m)
Debt / EBITDA = -0.07 (negative EBITDA) (Net Debt 6.07m / EBITDA -81.3m)
Debt / FCF = -0.23 (negative FCF - burning cash) (Net Debt 6.07m / FCF TTM -26.9m)
Total Stockholder Equity = 766.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -8.77% (Net Income -87.6m / Total Assets 999.4m)
RoE = -11.43% (Net Income TTM -87.6m / Total Stockholder Equity 766.4m)
RoCE = -10.85% (EBIT -94.4m / Capital Employed (Equity 766.4m + L.T.Debt 103.4m))
RoIC = -12.51% (negative operating profit) (NOPAT -95.7m / Invested Capital 765.3m)
WACC = 8.75% (E(5.04b)/V(5.14b) * Re(8.81%) + D(104.3m)/V(5.14b) * Rd(5.56%) * (1-Tc(-0.01)))
Discount Rate = 8.81% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 8.07%
Fair Price DCF = unknown (Cash Flow -26.9m)
EPS Correlation: 80.30 | EPS CAGR: 43.00% | SUE: 0.92 | # QB: 1
Revenue Correlation: 97.75 | Revenue CAGR: 25.68% | SUE: 4.0 | # QB: 6

Additional Sources for GKOS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle